Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41
The conserved internal trimeric coiled-coil of the N-heptad repeat (N-HR) of HIV-1 gp41 is transiently exposed during the fusion process by forming a pre-hairpin intermediate, thus representing an attractive target for the design of fusion inhibitors and neutralizing antibodies. In previous studies we reported a series of broadly neutralizing mini-antibodies derived from a synthetic naïve human combinatorial antibody library by panning against a mimetic of the trimeric N-HR coiled coil, followed by affinity maturation using targeted diversification of the CDR-H2 loop. Here we report crystal structures of the N-HR mimetic 5-Helix with two Fabs that represent the extremes of this series: Fab 8066 is broadly neutralizing across a wide panel of B and C type HIV-1 viruses, whereas Fab 8062 is non-neutralizing. The crystal structures reveal important differences in the conformations of the CDR-H2 loops in the complexes that propagate into other regions of the antigen-antibody interface, and suggest that both neutralization properties and affinity for the target can be attributed, at least in part, to the differences in the interactions of the CDR-H2 loops with the antigen. Furthermore, modeling of the complex of an N-HR trimer with three Fabs suggests that the CDR-H2 loop may be involved in close intermolecular contacts between neighboring antibody molecules, and that such contacts may hinder the formation of complexes between the N-HR trimer and more than one antibody molecule depending on the conformation of the bound CDR-H2 loop which is defined by its interactions with antigen. Comparison with the crystal structure of the complex of 5-Helix with another neutralizing monoclonal antibody known as D5, derived using an entirely different antibody library and panning procedure, reveals remarkable convergence in the optimal sequence and conformation of the CDR-H2 loop.
Vyšlo v časopise:
Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001182
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1001182
Souhrn
The conserved internal trimeric coiled-coil of the N-heptad repeat (N-HR) of HIV-1 gp41 is transiently exposed during the fusion process by forming a pre-hairpin intermediate, thus representing an attractive target for the design of fusion inhibitors and neutralizing antibodies. In previous studies we reported a series of broadly neutralizing mini-antibodies derived from a synthetic naïve human combinatorial antibody library by panning against a mimetic of the trimeric N-HR coiled coil, followed by affinity maturation using targeted diversification of the CDR-H2 loop. Here we report crystal structures of the N-HR mimetic 5-Helix with two Fabs that represent the extremes of this series: Fab 8066 is broadly neutralizing across a wide panel of B and C type HIV-1 viruses, whereas Fab 8062 is non-neutralizing. The crystal structures reveal important differences in the conformations of the CDR-H2 loops in the complexes that propagate into other regions of the antigen-antibody interface, and suggest that both neutralization properties and affinity for the target can be attributed, at least in part, to the differences in the interactions of the CDR-H2 loops with the antigen. Furthermore, modeling of the complex of an N-HR trimer with three Fabs suggests that the CDR-H2 loop may be involved in close intermolecular contacts between neighboring antibody molecules, and that such contacts may hinder the formation of complexes between the N-HR trimer and more than one antibody molecule depending on the conformation of the bound CDR-H2 loop which is defined by its interactions with antigen. Comparison with the crystal structure of the complex of 5-Helix with another neutralizing monoclonal antibody known as D5, derived using an entirely different antibody library and panning procedure, reveals remarkable convergence in the optimal sequence and conformation of the CDR-H2 loop.
Zdroje
1. BergerEA
MurphyPM
FarberJM
1999 Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17 657 700
2. EckertDM
KimPS
2001a Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70 777 810
3. FurutaRA
WildCT
WengY
WeissCD
1998 Capture of an early fusion-active conformation of HIV-1 gp41. Nature Struct Biol 5 276 279
4. ChanDC
KimPS
1998 HIV entry and its inhibition. Cell 93 681 684
5. MelikyanGB
MarkosyanRM
HemmatiH
DelmedicoMK
LambertDM
2000 Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151 413 423
6. GalloSA
FinneganCM
ViardM
RavivY
DimitrovA
2003 The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614 36 50
7. ChanDC
FassD
BergerJM
KimPS
1997 Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 263 273
8. WeissenhornW
DessenA
HarrisonSC
SkehelJJ
WileyDC
1997 Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 426 430
9. TanK
LiuJ
WangJ
ShenS
LuM
1997 Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94 12303 12308
10. CaffreyM
CaiM
KaufmanJ
StahlSJ
WingfieldPT
1998 Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17 4572 4584
11. WildC
OasT
McDanalC
BolognesiD
MatthewsT
1992 A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 10537 10541
12. JiangS
LinK
StrickN
NeurathAR
1993 HIV-1 inhibition by a peptide. Nature 365 113
13. WildCT
ShugarsDC
GreenwellTK
McDanalCB
MatthewsTJ
1994 Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91 9770 9774
14. EckertDM
MalashkevichVN
HongLH
CarrPA
KimPS
1999 Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 103 115
15. RootMJ
KayMS
KimPS
2001 Protein design of an HIV-1 entry inhibitor. Science 291 884 888
16. LouisJM
BewleyCA
CloreGM
2001 Design and properties of NCCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 276 29485 29489
17. ZwickMB
LabrijnAF
WangM
SpenlehauerC
SaphireEO
2001 Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. J Virol 75 10892 10905
18. EckertDM
KimPS
2001b Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 98 11187 11192
19. BewleyCA
LouisJM
GhirlandoR
CloreGM
2002 Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 277 14238 14245
20. GoldingH
ZaitsevaM
de RosnyE
KingLR
ManischewitzJ
2002 Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76 6780 6790
21. LouisJM
NesheiwatI
ChangL
CloreGM
BewleyCA
2003 Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278 20278 20285
22. RootMJ
StegerHK
2004 HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10 1805 1825
23. MatthewsT
SalgoM
GreenbergM
ChungJ
DeMasiR
2004 Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Rev Drug Discov 3 215 225
24. LouisJM
BewleyCA
GustchinaE
AnianaA
CloreGM
2005 Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353 945 951
25. GustchinaE
HummerG
BewleyCA
CloreGM
2005 Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem 48 3036 3044
26. GustchinaE
LouisJM
BewleyCA
CloreGM
2006 Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. J Mol Biol 364 283 289
27. StegerHK
RootMJ
2006 Kinetic dependence to HIV-1 entry inhibition. J Biol Chem 281 25813 25821
28. EckertDM
ShiY
KimS
WelchBD
KangE
2008 Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 17 2091 2100
29. GustchinaE
BewleyCA
CloreGM
2008 Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J Virol 82 10032 10041
30. HrinR
MontgomeryDL
WangF
CondraJH
AnZ
2008 Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24 1537 1544
31. KahleKM
StegerHK
RootMJ
2009 Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 5 e1000674
32. BianchiE
JoyceJG
MillerMD
FinnefrockAC
LiangX
(Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107 10655 10660
33. CortiD
LangedijkJP
HinzA
SeamanMS
VanzettaF
(Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5 e8805
34. MillerMD
GeleziunasR
BianchiE
LennardS
HrinR
2005 A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102 14759 14764
35. GustchinaE
LouisJM
LamSN
BewleyCA
CloreGM
2007 A Monoclonal Fab Derived From a Human Non-Immune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse HIV-1 Strains. J Virol 81 12946 12953
36. ChoudhryV
ZhangMY
SidorovIA
LouisJM
HarrisI
2007 Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 79 90
37. ZhangMY
VuBK
ChoudharyA
LuH
HumbertM
2008 Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol 82 6869 6879
38. NelsonJD
KinkeadH
BrunelFM
LeamanD
JensenR
2008 Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377 170 183
39. GustchinaE
LouisJM
FrischC
YleraF
LechnerA
2009 Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393 112 119
40. MontgomeryDL
WangYJ
HrinR
LuftigM
SuB
2009 Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 1 462 474
41. LuftigMA
MattuM
Di GiovineP
GeleziunasR
HrinR
2006 Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Struct Mol Biol 13 740 747
42. RotheC
UrlingerS
LohningC
PrasslerJ
StarkY
2008 The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376 1182 1200
43. ReynoldsC
DamerellD
JonesS
2009 ProtorP: a protein-protein interaction analysis server. Bioinformatics 25 413 414
44. KuikenC
FoleyB
MarxP
WolinskyS
LeitnerT
2009 HIV Sequence Compendium 2009. Los Alamos Theoretical Biology and Biophysics Group, Los Alamos National Laboratory 352 359
45. HuntDF
YatesJR3rd
ShabanowitzJ
WinstonS
HauerCR
1986 Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci U S A 83 6233 6237
46. ShevchenkoA
WilmM
VormO
MannM
1996 Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68 850 858
47. YuYQ
GilarM
LeePJ
BouvierES
GeblerJC
2003 Enzyme-friendly, mass spectrometry-compatible surfactant for in-solution enzymatic digestion of proteins. Anal Chem 75 6023 6028
48. McCoyAJ
Grosse-KunstleveRW
AdamsPD
WinnMD
StoroniLC
2007 Phaser crystallographic software. J Appl Crystallogr 40 658 674
49. MurshudovGN
VaginAA
DodsonEJ
1997 Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 240 255
50. EmsleyP
CowtanK
2004 Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 2126 2132
51. ChothiaC
LeskAM
1987 Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196 901 917
52. KuszewskiJ
GronenbornAM
CloreGM
1999 Improving the packing and accuracy of NMR structures with a pseudopotential for the radius of gyration. J Am Chem soc 121 2337 2338
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 11
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Zn Inhibits Coronavirus and Arterivirus RNA Polymerase Activity and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
- The Female Lower Genital Tract Is a Privileged Compartment with IL-10 Producing Dendritic Cells and Poor Th1 Immunity following Infection
- Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41
- The Arabidopsis Resistance-Like Gene Is Activated by Mutations in and Contributes to Resistance to the Bacterial Effector AvrRps4